 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 12» |
- || volrustomig (MEDI5752) / AstraZeneca, rilvegostomig (AZD2936) / AstraZeneca, sabestomig (AZD7789) / AstraZeneca
Enrollment open: MST01-AZN-05: PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC (clinicaltrials.gov) - Apr 30, 2024
P1, N=15, Recruiting, Sponsor: Presage Biosciences
Not yet recruiting --> Recruiting
- || datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Pan tumor, Metastases: Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) (clinicaltrials.gov) - Apr 25, 2024
P2, N=531, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Trial completion date: Mar 2025 --> Aug 2026 | Trial primary completion date: Mar 2025 --> Aug 2026
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, rilvegostomig (AZD2936) / AstraZeneca
A phase 3, randomized study of adjuvant rilvegostomig plus chemotherapy in resected biliary tract cancer: ARTEMIDE-Biliary01. (Hall A; Poster Bd #: 169b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3928;
P3
Additional endpoints include progression-free survival following recurrence, patient-reported tolerability, and safety. Enrollment has begun, and approximately 200 sites will be recruiting globally across Asia, Australia, Europe, North America, and South America.
- GEMINI-Hepatobiliary: A phase 2 study of novel first-line immuno-oncology-based treatments in patients with advanced hepatobiliary cancers. (Hall A; Poster Bd #: 163b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3916;
P2
Early-phase studies have demonstrated the efficacy of volrustomig (volru; anti-PD-1/CTLA-4 bispecific humanized IgG1 monoclonal antibody [mAb]) in patients (pts) with non-small-cell lung cancer (NSCLC) and renal cell carcinoma, and of rilvegostomig (rilve; anti-PD-1/TIGIT bispecific humanized IgG1 mAb) in pts with NSCLC, along with manageable safety profiles...Pts will be treated with volru as monotherapy or in combination with bevacizumab or lenvatinib...Pts will be treated with gemcitabine + cisplatin with either rilve or volru...The study is currently recruiting at sites in the US, Asia, and Europe. GEMINI-Hepatobiliary master protocol design.
- GEMINI-Gastric: A phase 2 study of novel treatment combinations in patients with locally advanced unresectable or metastatic gastric cancers. (Hall A; Poster Bd #: 161a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3911;
P2
Sample sizes have been selected to provide adequate precision for the primary endpoints. The study is currently recruiting at sites in the US, Europe, and Asia.
- rilvegostomig (AZD2936) / AstraZeneca
Molecular residual disease (MRD) interception in locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC): MERIDIAN study. (Hall A; Poster Bd #: 433b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3572;
Rilvegostomig (AZD2936) is a monovalent bispecific TIGIT/PD-1 antibody that has shown acceptable safety in phase I studies, currently in phase III studies...Exploratory analyses include: ctDNA detection using other assays (HPV DNA, methylated ctDNA), ctDNA detection in part E and beyond W10 in part D, quality of life assessments (FACT-ICM, EORTC-HN43), health economics and radiomics. As of February 2024, 19 patients are recruited.
- || volrustomig (MEDI5752) / AstraZeneca, rilvegostomig (AZD2936) / AstraZeneca, sabestomig (AZD7789) / AstraZeneca
New P1 trial: MST01-AZN-05: PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC (clinicaltrials.gov) - Apr 16, 2024
P1, N=15, Not yet recruiting, Sponsor: Presage Biosciences
- |||||||||| rilvegostomig (AZD2936) / AstraZeneca, datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca
New P3 trial, Combination therapy, Monotherapy, IO biomarker, Metastases: TROPION-Lung10: Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ? 50%) and Without Actionable Genomic Alterations (clinicaltrials.gov) - Apr 10, 2024
P3, N=675, Not yet recruiting, Sponsor: AstraZeneca
- Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Dual immune checkpoint inhibition enhances the anti-tumor activity of trastuzumab deruxtecan in preclinical models (Section 3) - Mar 5, 2024 - Abstract #AACR2024AACR_4155;
The anti-tumor activity of T-DXd in combination with volrustomig, a monovalent bispecific antibody targeting PD-1 and CTLA-4, was also assessed in hu-CD34+ NSG mice bearing HER2-low Caki-1 renal cell carcinoma tumors...Pharmacodynamic analysis revealed how the combination of T-DXd and PD-1/TIGIT inhibition increased tumoral NK cells (3.2-fold, P <0.001) and CD8+ T cells (3.8-fold, P <0.001) relative to vehicle. Consistent with findings in syngeneic models, the combination of T-DXd with a bispecific PD-1/CTLA-4 inhibitor also enhanced tumor growth inhibition in a humanised Caki-1 model (121%) compared to T-DXd alone (72%) (P <0.001).ConclusionsThese data provide insight into the clinical activity observed with T-DXd and provide scientific rationale for combination strategies with novel, bispecific IO agents targeting CTLA-4 or TIGIT in addition to the PD-1/PD-L1 axis.
- | Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Metastases: MAGELLAN: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (clinicaltrials.gov) - Mar 2, 2024
P1, N=175, Active, not recruiting, Sponsor: AstraZeneca
Consistent with findings in syngeneic models, the combination of T-DXd with a bispecific PD-1/CTLA-4 inhibitor also enhanced tumor growth inhibition in a humanised Caki-1 model (121%) compared to T-DXd alone (72%) (P <0.001).ConclusionsThese data provide insight into the clinical activity observed with T-DXd and provide scientific rationale for combination strategies with novel, bispecific IO agents targeting CTLA-4 or TIGIT in addition to the PD-1/PD-L1 axis. Trial completion date: May 2023 --> Mar 2026
- || Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Phase classification, Trial completion date, Trial primary completion date, Monotherapy, Metastases: Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) (clinicaltrials.gov) - Feb 19, 2024
P2, N=357, Recruiting, Sponsor: AstraZeneca
Trial completion date: May 2023 --> Mar 2026 Phase classification: P1b/2 --> P2 | Trial completion date: Sep 2025 --> Jul 2026 | Trial primary completion date: Sep 2025 --> Jul 2026
- ||| volrustomig (MEDI5752) / AstraZeneca, rilvegostomig (AZD2936) / AstraZeneca
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Immunomodulating, Metastases: Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (clinicaltrials.gov) - Feb 15, 2024
P2, N=260, Recruiting, Sponsor: AstraZeneca
Phase classification: P1b/2 --> P2 | Trial completion date: Sep 2025 --> Jul 2026 | Trial primary completion date: Sep 2025 --> Jul 2026 N=180 --> 260 | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2024 --> Nov 2025
- || datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca
Phase classification, Enrollment change, Combination therapy, Metastases: TROPION-Lung04: Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Dec 21, 2023
P1, N=321, Recruiting, Sponsor: AstraZeneca
N=180 --> 260 | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2024 --> Nov 2025 Phase classification: P1b --> P1 | N=232 --> 321
- |||||| rilvegostomig (AZD2936) / AstraZeneca
Enrollment open, Combination therapy: ARTEMIDE-Bil01: Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) (clinicaltrials.gov) - Dec 19, 2023
P3, N=750, Recruiting, Sponsor: AstraZeneca
Phase classification: P1b --> P1 | N=232 --> 321 Not yet recruiting --> Recruiting
- || rilvegostomig (AZD2936) / AstraZeneca
Trial primary completion date, Metastases: ARTEMIDE-01: A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (clinicaltrials.gov) - Dec 19, 2023
P1/2, N=192, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2023 --> Jan 2026
- ||| Enrollment change, Metastases: Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Dec 6, 2023
P2, N=240, Recruiting, Sponsor: AstraZeneca
Trial primary completion date: Dec 2023 --> Jan 2026 N=80 --> 240
- | rilvegostomig (AZD2936) / AstraZeneca
Trial completion date, Metastases: ARTEMIDE-01: A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (clinicaltrials.gov) - Nov 7, 2023
P1/2, N=192, Recruiting, Sponsor: AstraZeneca
N=80 --> 240 Trial completion date: Jul 2025 --> Jan 2026
- |||||||||| rilvegostomig (AZD2936) / AstraZeneca
New P3 trial, Combination therapy: ARTEMIDE-Bil01: Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) (clinicaltrials.gov) - Oct 31, 2023
P3, N=750, Not yet recruiting, Sponsor: AstraZeneca
- || datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy, Metastases: TROPION-Lung04: Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Aug 18, 2023
P1b, N=232, Recruiting, Sponsor: AstraZeneca
Trial completion date: Jul 2025 --> Jan 2026 Trial completion date: Feb 2025 --> Jan 2026 | Trial primary completion date: Feb 2025 --> Jan 2026
- rilvegostomig (AZD2936) / AstraZeneca
Preliminary efficacy and safety of rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-pretreated advanced/metastatic non-small-cell lung cancer (NSCLC): ARTEMIDE-01 () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2937;
P1/2
Trial completion date: Feb 2025 --> Jan 2026 | Trial primary completion date: Feb 2025 --> Jan 2026 Further investigation is ongoing in CPI-na
- ||| rilvegostomig (AZD2936) / AstraZeneca
Enrollment open, Metastases: MERIDIAN: Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC (clinicaltrials.gov) - Jul 20, 2023
P2, N=200, Recruiting, Sponsor: University Health Network, Toronto
Further investigation is ongoing in CPI-na Not yet recruiting --> Recruiting
- ||| volrustomig (MEDI5752) / AstraZeneca, rilvegostomig (AZD2936) / AstraZeneca
Enrollment change, Combination therapy, Monotherapy, Immunomodulating, Metastases: Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (clinicaltrials.gov) - Jul 17, 2023
P2, N=180, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting N=120 --> 180
- || rilvegostomig (AZD2936) / AstraZeneca
Trial completion date, Trial primary completion date, Metastases: MERIDIAN: Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC (clinicaltrials.gov) - Jul 3, 2023
P2, N=200, Not yet recruiting, Sponsor: University Health Network, Toronto
N=120 --> 180 Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2025 --> Jul 2026
- || Imfinzi (durvalumab) / AstraZeneca
Enrollment change, Trial completion date, Trial primary completion date, Metastases: MAGELLAN: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (clinicaltrials.gov) - Jun 1, 2023
P1, N=175, Active, not recruiting, Sponsor: AstraZeneca
Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2025 --> Jul 2026 N=258 --> 175 | Trial completion date: Mar 2026 --> May 2023 | Trial primary completion date: Mar 2026 --> May 2023
- || Trial completion date, Trial primary completion date, Metastases: Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - May 19, 2023
P2, N=80, Recruiting, Sponsor: AstraZeneca
N=258 --> 175 | Trial completion date: Mar 2026 --> May 2023 | Trial primary completion date: Mar 2026 --> May 2023 Trial completion date: Mar 2025 --> Feb 2026 | Trial primary completion date: Jun 2024 --> Aug 2025
- ||| volrustomig (MEDI5752) / AstraZeneca, rilvegostomig (AZD2936) / AstraZeneca
Enrollment open, Combination therapy, Monotherapy, Immunomodulating, Metastases: Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (clinicaltrials.gov) - May 15, 2023
P2, N=120, Recruiting, Sponsor: AstraZeneca
Trial completion date: Mar 2025 --> Feb 2026 | Trial primary completion date: Jun 2024 --> Aug 2025 Not yet recruiting --> Recruiting
- rilvegostomig (AZD2936) / AstraZeneca
Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD2936, a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-experienced advanced/metastatic non-small-cell lung cancer (NSCLC): First report of ARTEMIDE-01. (On Demand | Hall A; Poster Bd # 38) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3459;
P1/2
In this interim analysis, AZD2936 showed an acceptable safety profile and preliminary antitumor activity in pts with advanced/metastatic NSCLC previously treated with standard therapy including CPIs. Further exploration of AZD2936 in CPI-na
- datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca
TROPION-Lung04: Phase 1b, multicenter study of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy (On Demand | Hall A; Poster Bd # 353b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1857;
P1b
Further exploration of AZD2936 in CPI-na Details of cohorts 1
- | datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca
Trial completion date, Combination therapy, Metastases: TROPION-Lung04: Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Apr 12, 2023
P1b, N=232, Recruiting, Sponsor: AstraZeneca
Details of cohorts 1 Trial completion date: Mar 2026 --> Feb 2025
- |||| volrustomig (MEDI5752) / AstraZeneca, rilvegostomig (AZD2936) / AstraZeneca
New P2 trial, Combination therapy, Monotherapy, Immunomodulating, Metastases: Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (clinicaltrials.gov) - Mar 20, 2023
P2, N=120, Not yet recruiting, Sponsor: AstraZeneca
- || Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Trial completion date, Trial primary completion date, Monotherapy, Metastases: Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) (clinicaltrials.gov) - Mar 17, 2023
P1b/2, N=351, Recruiting, Sponsor: AstraZeneca
Trial completion date: Mar 2026 --> Feb 2025 Trial completion date: Dec 2024 --> Jul 2025 | Trial primary completion date: Dec 2024 --> Jul 2025
- |||| New P2 trial, Metastases: Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Jan 27, 2023
P2, N=80, Recruiting, Sponsor: AstraZeneca
- ||| rilvegostomig (AZD2936) / AstraZeneca
Enrollment change, Metastases: ARTEMIDE-01: A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (clinicaltrials.gov) - Jan 26, 2023
P1/2, N=192, Recruiting, Sponsor: AstraZeneca
Trial completion date: Dec 2024 --> Jul 2025 | Trial primary completion date: Dec 2024 --> Jul 2025 N=147 --> 192
- || rilvegostomig (AZD2936) / AstraZeneca
Trial initiation date, Metastases: MERIDIAN: Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC (clinicaltrials.gov) - Jan 10, 2023
P2, N=200, Not yet recruiting, Sponsor: University Health Network, Toronto
N=147 --> 192 Initiation date: Jul 2022 --> Mar 2023
- || datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: TROPION-Lung04: Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Nov 10, 2022
P1b, N=232, Recruiting, Sponsor: AstraZeneca
Initiation date: Jul 2022 --> Mar 2023 N=68 --> 232 | Trial completion date: Jun 2024 --> Mar 2026 | Trial primary completion date: Sep 2023 --> Dec 2024
- || Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Trial completion date, Trial primary completion date, Monotherapy, Metastases: Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) (clinicaltrials.gov) - Oct 24, 2022
P1b/2, N=315, Recruiting, Sponsor: AstraZeneca
N=68 --> 232 | Trial completion date: Jun 2024 --> Mar 2026 | Trial primary completion date: Sep 2023 --> Dec 2024 Trial completion date: Oct 2023 --> Nov 2024 | Trial primary completion date: Oct 2023 --> Nov 2024
- AZD2936 / AstraZeneca
Preclinical studies support clinical development of AZD2936, a monovalent bispecific humanized antibody targeting PD-1 and TIGIT (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_804;
P1/2
These preclinical results support the ongoing clinical development of AZD2936 in patients with cancer. Trial Registration NCT04995523
- | rilvegostomig (AZD2936) / AstraZeneca
Trial completion date, Metastases: ARTEMIDE-01: A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (clinicaltrials.gov) - Sep 21, 2022
P1/2, N=147, Recruiting, Sponsor: AstraZeneca
Trial Registration NCT04995523 Trial completion date: Dec 2023 --> Jul 2025
- || Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Trial completion date, Trial primary completion date, Monotherapy, Metastases: Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) (clinicaltrials.gov) - Sep 19, 2022
P1b/2, N=255, Recruiting, Sponsor: AstraZeneca
Trial completion date: Dec 2023 --> Jul 2025 Trial completion date: Jul 2023 --> Oct 2023 | Trial primary completion date: Jul 2023 --> Oct 2023
- |||| datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca
Enrollment open, Combination therapy, Monotherapy, Pan tumor, Metastases: Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) (clinicaltrials.gov) - Sep 19, 2022
P2, N=531, Recruiting, Sponsor: AstraZeneca
Trial completion date: Jul 2023 --> Oct 2023 | Trial primary completion date: Jul 2023 --> Oct 2023 Not yet recruiting --> Recruiting
- ||||| datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca
New P2 trial, Combination therapy, Monotherapy, Pan tumor, Metastases: Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) (clinicaltrials.gov) - Aug 5, 2022
P2, N=451, Not yet recruiting, Sponsor: AstraZeneca
- |||| domvanalimab (AB154) / Arcus Biosci, Gilead, Otsuka, AZD2936 / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
$AZN pressing on with $CGEN-derived PD-1 x Tigit bispecific AZD2936. Separately Imfinzi + $RCUS domvanalimab is in ph3 for stage III NSCLC (Twitter) - Jul 28, 2022
- || datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy, Metastases: TROPION-Lung04: Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jul 19, 2022
P1b, N=68, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Trial completion date: Dec 2024 --> Jun 2024 | Trial primary completion date: Mar 2023 --> Sep 2023
- |||| rilvegostomig (AZD2936) / AstraZeneca
New P2 trial, Metastases: MERIDIAN: Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC (clinicaltrials.gov) - Jun 9, 2022
P2, N=200, Not yet recruiting, Sponsor: University Health Network, Toronto
- || Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Trial primary completion date, Metastases: MAGELLAN: A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (clinicaltrials.gov) - May 5, 2022
P1, N=212, Active, not recruiting, Sponsor: AstraZeneca
Trial completion date: Dec 2024 --> Jun 2024 | Trial primary completion date: Mar 2023 --> Sep 2023 Trial completion date: Jan 2024 --> Mar 2026 | Trial primary completion date: Jan 2024 --> Mar 2026
- || datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca
Enrollment change, Combination therapy, Metastases: TROPION-Lung04: Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Dec 20, 2021
P1b, N=68, Recruiting, Sponsor: Daiichi Sankyo, Inc.
Trial completion date: Jan 2024 --> Mar 2026 | Trial primary completion date: Jan 2024 --> Mar 2026 N=120 --> 68
- |||| AZD2936 / AstraZeneca
$AZN does Tigit (AZD2936 = anti-TIGIT/anti-PD-1 bispecific MAb) $ITOS $CGEN $RHHBY $MRK (Twitter) - Nov 12, 2021
- ||| rilvegostomig (AZD2936) / AstraZeneca
Enrollment open, Metastases: ARTEMIDE-01: A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (clinicaltrials.gov) - Oct 10, 2021
P1/2, N=147, Recruiting, Sponsor: AstraZeneca
N=120 --> 68 Not yet recruiting --> Recruiting
- || Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Trial completion date, Trial primary completion date, Monotherapy, Metastases: Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) (clinicaltrials.gov) - Sep 5, 2021
P1b/2, N=255, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Trial completion date: Mar 2023 --> Jul 2023 | Trial primary completion date: Mar 2023 --> Jul 2023
- |||| rilvegostomig (AZD2936) / AstraZeneca
New P1/2 trial, Metastases: ARTEMIDE-01: A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (clinicaltrials.gov) - Aug 8, 2021
P1/2, N=147, Not yet recruiting, Sponsor: AstraZeneca